Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zydelig | Idelalisib | Chronic lymphocytic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revlimid | Lenalidomide | Multiple Myeloma, newly diagnosed | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vectibix | Panitumumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Beqvez | fidanacogene elaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab vedotin | Hodgkin Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 20, 2024